SEC Form 4 · accession 0001209191-19-008467
Evoke Pharma Inc · EVOK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Gonyer
Officer — President and CEO · Director
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.94 | Feb 6, 2019 | A | 225,000 | A | — | Feb 5, 2029 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The total number of shares of common stock subject to the option vests in 48 equal monthly installments over the four-year period beginning on January 1, 2019, subject to the reporting person's continued service to the Issuer through each such vesting date.